Diabetic macular edema (DME) is the leading cause of vision impairment in diabetic patients. Although anti-VEGF agents are the first-line treatment, challenges such as drug resistance, frequent injections, and refractory cases persist. This article systematically reviews optimization strategies for DME treatment: regarding first-line anti-VEGF therapy, it discusses drug alternative regimens, precision treatment based on OCT classification, and the application of novel bispecific antibody drugs and sustained-release delivery systems; for refractory DME, it analyzes glucocorticoid alternative therapy, methotrexate application, and surgical interventions such as cystotomy and precise laser photocoagulation; in view of the high incidence of DME after cataract surgery in diabetic populations, it elaborates on perioperative prevention and control strategies from the aspects of systemic metabolic management, OCT and OCTA imaging evaluation, artificial intelligence prediction models, and aqueous humor inflammatory factor monitoring; finally, it prospects future research directions such as nanotechnology, biomarker-targeted therapy, and nutritional metabolic intervention, aiming to provide references for clinical individualized precision treatment.

Ying He, Zuhai Zhang, Jingwang Chen. Research Progress on Individualized Treatment of Diabetic Macular Edema. International Journal of Frontiers in Medicine (2026), Vol. 8, Issue 2: 1-10. https://doi.org/10.25236/IJFM.2026.080201.

[1] Zhang, J. et al. Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications. Cells 11 (2022). https://doi.org/10.3390/cells11213362

[2] Society, C. D. Guidelines for the Prevention and Treatment of Diabetes in China (2024 Edition) (Excerpt 1). Chinese Journal of Practical Internal Medicine 45, 864-874+892 (2025). https://doi.org/10.3760/cma.j.cn115791-20241203-00705

[3] Tsui, C. K. et al. Prevalence, incidence, and risk factors of diabetic retinopathy and macular edema in patients with early and late-onset type 2 diabetes mellitus. J Diabetes Investig 16, 1254-1262 (2025). https://doi.org/10.1111/jdi.70027

[4] Fung, T. H., Patel, B., Wilmot, E. G. & Amoaku, W. M. Diabetic retinopathy for the non-ophthalmologist. Clin Med (Lond) 22, 112-116 (2022). https://doi.org/10.7861/clinmed.2021-0792

[5] Petkova-Parlapanska, K. et al. Systematic Inflammation and Oxidative Stress Elevation in Diabetic Retinopathy and Diabetic Patients with Macular Edema. Int J Mol Sci 26 (2025). https://doi.org/10.3390/ijms26083810

[6] O'Leary, F. & Campbell, M. The blood-retina barrier in health and disease. FEBS J 290, 878-891 (2023). https://doi.org/10.1111/febs.16330

[7] Uemura, A. et al. VEGFR1 signaling in retinal angiogenesis and microinflammation. Prog Retin Eye Res 84, 100954 (2021). https://doi.org/10.1016/j.preteyeres.2021.100954

[8] Tabano, D. et al. The Economic Burden of Anti-Vascular Endothelial Growth Factor on Patients and Caregivers in the UK, Europe, and North America. Ophthalmol Ther 14, 1869-1892 (2025). https://doi.org/10.1007/s40123-025-01180-5

[9] Becker, C. et al. Cataract in patients with diabetes mellitus-incidence rates in the UK and risk factors. Eye (Lond) 32, 1028-1035 (2018). https://doi.org/10.1038/s41433-017-0003-1

[10] Albert-Garay, J. S., Icazbalceta de la Pena, J. A., Medina-Arellano, A. E., Gonzalez-Salinas, R. & Ochoa-de la Paz, L. D. Downregulation of TRPV4 and LRRC8A in Crystalline Lenses of Diabetic Patients May Contribute to Cataractogenesis. Clin Ophthalmol 19, 4787-4799 (2025). https://doi.org/10.2147/OPTH.S557358

[11] Sukkee, J., Jirarattanasopa, P., Ratanasukon, M., Bhurayanontachai, P. & Dangboon Tsutsumi, W. Association between the progression of diabetic retinopathy and cataract surgery in patients with diabetes: A retrospective study in Thailand. Medicine (Baltimore) 104, e45349 (2025). https://doi.org/10.1097/MD.0000000000045349

[12] Yao, H., Yang, Z., Cheng, Y. & Shen, X. Macular changes following cataract surgery in eyes with early diabetic retinopathy: an OCT and OCT angiography study. Front Med (Lausanne) 10, 1290599 (2023). https://doi.org/10.3389/fmed.2023.1290599

[13] Fresta, C. G. et al. A New Human Blood-Retinal Barrier Model Based on Endothelial Cells, Pericytes, and Astrocytes. Int J Mol Sci 21 (2020). https://doi.org/10.3390/ijms21051636

[14] Zarei-Ghanavati, S., Hadi, Y., Habibi, A., Ashraf Khorasani, M. & Yoo, S. H. Cataract and diabetes: review of the literature. J Cataract Refract Surg 50, 1275-1283 (2024). https://doi.org/10.1097/j.jcrs.0000000000001547

[15] Koksaldi, S., Karti, O. & Saatci, A. O. Anti-vascular endothelial growth factor therapies in ophthalmology. Med Hypothesis Discov Innov Ophthalmol 14, 107-135 (2025). https://doi.org/10.51329/mehdiophthal1526

[16] Perez-Gutierrez, L. & Ferrara, N. Biology and therapeutic targeting of vascular endothelial growth factor A. Nat Rev Mol Cell Biol 24, 816-834 (2023). https://doi.org/10.1038/s41580-023-00631-w

[17] Tatsumi, T. Current Treatments for Diabetic Macular Edema. Int J Mol Sci 24 (2023). https://doi.org/10.3390/ijms24119591

[18] Yuen, Y. S. et al. Real-World Evidence in the Management of Diabetic Macular Edema with Intravitreal Anti-VEGFs in Asia: A Systematic Literature Review. Clin Ophthalmol 16, 3503-3526 (2022). https://doi.org/10.2147/OPTH.S378392

[19] Hostovsky, A., Moroz, I. & Katz, G. Aflibercept monotherapy or bevacizumab first for diabetic macular edema. Indian J Ophthalmol 72, S260-S264 (2024). https://doi.org/10.4103/IJO.IJO_2107_23

[20] Xing, P., Meng, B., Hu, X., Qu, W. & Wang, S. Switching to Conbercept in Diabetic Macular Edema After Unsatisfactory Response to Previous Intravitreal Injection of Ranibizumab. Clin Ophthalmol 17, 3491-3497 (2023). https://doi.org/10.2147/OPTH.S431145

[21] Nawar, A. E., Wasfy, T. & Shafik, H. M. Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection. BMC Ophthalmol 22, 287 (2022). https://doi.org/10.1186/s12886-022-02503-x

[22] Wang, X., He, X., Qi, F., Liu, J. & Wu, J. Different Anti-Vascular Endothelial Growth Factor for Patients With Diabetic Macular Edema: A Network Meta-Analysis. Front Pharmacol 13, 876386 (2022). https://doi.org/10.3389/fphar.2022.876386

[23] Zhang, X. et al. Efficacy of Antiangiogenic Drugs in the Treatment of Diabetic Macular Edema: A Bayesian Network Analysis. Front Pharmacol 12, 637667 (2021). https://doi.org/10.3389/fphar.2021.637667

[24] Jhaveri, C. D. et al. Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40. Ophthalmology 131, 967-974 (2024). https://doi.org/10.1016/j.ophtha.2024.01.037

[25] Panozzo, G. et al. Enhancing Diabetic Macular Edema Treatment Outcomes: Exploring the ESASO Classification and Structural OCT Biomarkers. Ophthalmol Ther 13, 1383-1398 (2024). https://doi.org/10.1007/s40123-024-00925-y

[26] Zhang, Y. et al. Treatment response to Conbercept of different types of diabetic macular edema classified based on optical coherence tomography. J South Med Univ 41, 1501-1508 (2021). https://doi.org/10.12122/j.issn.1673-4254.2021.10.08

[27] Zheng, H., Gong, Y., Cao, X., Li, W., & Zhang, P. Efficacy of conbercept in the treatment of different types of macular edema after cataract surgery in diabetic patients. International Eye Science, 20, 1967-1970 (2020). http: / / ies．ijo．cn

[28] Ciulla, T. A., Hussain, R. M., Taraborelli, D., Pollack, J. S. & Williams, D. F. Longer-Term Anti-VEGF Therapy Outcomes in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Vein Occlusion-Related Macular Edema: Clinical Outcomes in 130 247 Eyes. Ophthalmol Retina 6, 796-806 (2022). https://doi.org/10.1016/j.oret.2022.03.021

[29] Lim, J. I. et al. Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema. Ophthalmol Retina 9, 655-666 (2025). https://doi.org/10.1016/j.oret.2025.01.017

[30] Chandrasekaran, P. R. & Madanagopalan, V. G. KSI-301: antibody biopolymer conjugate in retinal disorders. Ther Adv Ophthalmol 13, 25158414211027708 (2021). https://doi.org/10.1177/25158414211027708

[31] Iglicki, M., Gonzalez, D. P., Loewenstein, A. & Zur, D. Next-generation anti-VEGF agents for diabetic macular oedema. Eye (Lond) 36, 273-277 (2022). https://doi.org/10.1038/s41433-021-01722-8

[32] Khanani, A. M. et al. Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial. JAMA Ophthalmol 143, 326-335 (2025). https://doi.org/10.1001/jamaophthalmol.2025.0006

[33] Veiga Reis, F. et al. Combined intravitreal dexamethasone and bevacizumab injection for the treatment of persistent diabetic macular edema (DexaBe study): a phase I clinical study. Int J Retina Vitreous 9, 13 (2023). https://doi.org/10.1186/s40942-023-00449-w

[34] Raizada, S. et al. Timing of Switching to Steroid Implants in Cases of Recalcitrant Diabetic Macular Edema Not Responding to Anti-vascular Endothelial Growth Factor (VEGF) Therapy: A Real-World Study. Cureus 16, e62385 (2024). https://doi.org/10.7759/cureus.62385

[35] Darwisch, W. et al. Real-Life Results after the Administration of a Single 0.19 mg Fluocinolone Acetonide (ILUVIEN(R)) Implant in Patients with Refractory Diabetic Macular Edema. Ophthalmic Res 67, 600-610 (2024). https://doi.org/10.1159/000540459

[36] El Rayes, E. N. & Leila, M. Visual function and retinal morphological changes after single suprachoroidal delivery of fluocinolone acetonide (Iluvien(R)) implant in eyes with chronic diabetic macular edema. Int J Retina Vitreous 9, 20 (2023). https://doi.org/10.1186/s40942-023-00458-9

[37] Sadhukhan, K. & Naskar, S. Role of Combined Therapy of Intravitreal Ranibizumab and Dexamethasone in Refractory Diabetic Macular Edema: a Retrospective Study. Maedica (Bucur) 16, 615-619 (2021). https://doi.org/10.26574/maedica.2021.16.4.615

[38] Cornish, E. E. et al. Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema. Br J Ophthalmol 107, 79-83 (2023). https://doi.org/10.1136/bjophthalmol-2021-319839

[39] Abdi, F., Mohammadi, S. S. & Falavarjani, K. G. Intravitreal Methotrexate. J Ophthalmic Vis Res 16, 657-669 (2021). https://doi.org/10.18502/jovr.v16i4.9756

[40] Razzaghpour, N., Najafi, A., Sabouri, M. R., Ashoori, N. & Shahraki, K. Intravitreal injection of methotrexate in persistent diabetic macular edema: a 6-month study. Med Hypothesis Discov Innov Ophthalmol 12, 150-156 (2023). https://doi.org/10.51329/mehdiophthal1480

[41] Yamada, H. et al. Three-year outcomes of cystotomy and fibrinogen clot removal for diabetic macular edema with subfoveal cystoid macular edema. Sci Rep 15, 16019 (2025). https://doi.org/10.1038/s41598-025-01197-7

[42] Mitamura, M. et al. AI-based analysis of surgical outcomes in vitrectomy with and without cystotomy for refractory cystoid diabetic macular edema. Sci Rep 15, 14629 (2025). https://doi.org/10.1038/s41598-025-93847-z

[43] Ikegami, Y. et al. Navigated direct photocoagulation with a 30-ms short-pulse laser for treating microaneurysms in diabetic macular edema exhibits a high closure rate. Sci Rep 13, 6092 (2023). https://doi.org/10.1038/s41598-023-33260-6

[44] Tanaka, H., Numa, K., Yoshioka, H., Aoki, T. & Sotozono, C. Surgical Management of Foveal Telangiectatic Capillaries in Diabetic Macular Edema. Cureus 17, e91026 (2025). https://doi.org/10.7759/cureus.91026

[45] C, R. H., T, S. & N, I. Is glycaemic control essential for cataract surgery among patients with diabetes mellitus? Bioinformation 21, 1011-1015 (2025). https://doi.org/10.6026/973206300211011

[46] Kim, M., Park, Y. G. & Park, Y. H. Cataract surgery and the risk of developing recurrence or progression of diabetic macular edema. PLoS One 20, e0328874 (2025). https://doi.org/10.1371/journal.pone.0328874

[47] Bek, T., Tilma, K. & la Cour, M. The risk for developing vision-threatening retinopathy after cataract surgery in diabetic patients depends on the postoperative follow-up time. Acta Ophthalmol 100, e719-e725 (2022). https://doi.org/10.1111/aos.14992

[48] Choudhary, M., Mohanty, G., Mohanty, S., N, S. & Bhadani, S. Macular and Choroidal Thickness Changes After Cataract Surgery in Diabetic and Non-diabetic Patients: A Prospective Optical Coherence Tomography (OCT) Study. Cureus 17, e95333 (2025). https://doi.org/10.7759/cureus.95333

[49] Yang, X. et al. Prediction of OCT contours of short-term response to anti-VEGF treatment for diabetic macular edema using generative adversarial networks. Photodiagnosis Photodyn Ther 52, 104482 (2025). https://doi.org/10.1016/j.pdpdt.2025.104482

[50] Song, T. et al. Construction of a predictive model for the efficacy of anti-VEGF therapy in macular edema patients based on OCT imaging: a retrospective study. Front Med (Lausanne) 12, 1505530 (2025). https://doi.org/10.3389/fmed.2025.1505530

[51] Kim, J. et al. Alterations in optical coherence tomography angiography parameters after cataract surgery in patients with diabetes. Sci Rep 14, 23814 (2024). https://doi.org/10.1038/s41598-024-73830-w

[52] Basiony, A. I., Mohamed Gad Marey, H., Ezzat Abdel Fattah, A. M. & Aly Zaky, M. Predictive value of optical coherence tomography angiography in management of diabetic macular edema. BMC Ophthalmol 24, 429 (2024). https://doi.org/10.1186/s12886-024-03540-4

[53] Vujosevic, S. et al. Role of inflammation in diabetic macular edema and neovascular age-related macular degeneration. Surv Ophthalmol 69, 870-881 (2024). https://doi.org/10.1016/j.survophthal.2024.07.006

[54] Xie, M. Aqueous-humor biomarkers and real-world efficacy of conbercept for diabetic macular edema: a prospective study in elderly patients. Front Endocrinol (Lausanne) 16, 1632878 (2025). https://doi.org/10.3389/fendo.2025.1632878

[55] Aaronson, A. et al. Relationship Between Prolonged Intraocular Inflammation and Macular Edema After Cataract Surgery. Transl Vis Sci Technol 10, 15 (2021). https://doi.org/10.1167/tvst.10.7.15

[56] Sultan, M. et al. Efficacy of preoperative 0.1% topical nepafenac in the prevention of cystoid macular edema after cataract surgery in diabetic patients. Pak J Pharm Sci 38, 1321-1327 (2025). https://doi.org/10.36721/PJPS.2025.38.4.REG.13237.1

[57] Akbas, Y. B. et al. Comparison of topical nepafenac 0.1% and 0.3% on aqueous flare and macular thickness in patients with pseudoexfoliation following cataract surgery. Indian J Ophthalmol 73, S424-S427 (2025). https://doi.org/10.4103/IJO.IJO_2916_24

[58] Pivic-Kovacevic, I. et al. Effect of Uncomplicated Ultrasound Phacoemulsification Cataract Surgery on Central Macular Thickness Changes in the Early Postoperative Period in Diabetic Patients. Acta Clin Croat 63, 619-625 (2024). https://doi.org/10.20471/acc.2024.63.03-04.21

[59] Meduri, A. et al. Role of Cold Balanced Salt Solution (BSS) in the Prophylaxis of Cystoid Macular Edema After Cataract Surgery: A Prospective Randomized Study. Clin Ophthalmol 15, 2519-2526 (2021). https://doi.org/10.2147/OPTH.S304146

[60] Guven, Y. Z., Isik, M. U., Ilguy, S. & Yozgat, Z. Phacoemulsification surgery in patients with diabetic macular edema: should intravitreal anti-VEGF therapy be performed before or simultaneously with surgery? Int J Ophthalmol 18, 637-641 (2025). https://doi.org/10.18240/ijo.2025.04.09

[61] Liu, Y. & Wu, N. Progress of Nanotechnology in Diabetic Retinopathy Treatment. Int J Nanomedicine 16, 1391-1403 (2021). https://doi.org/10.2147/IJN.S294807

[62] Wu, Y. et al. Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases. Adv Sci (Weinh) 11, e2403399 (2024). https://doi.org/10.1002/advs.202403399

[63] Xue, B. et al. Nanozyme eye drops for retinal barrier penetration and vasculopathy repair. Science advances 11, eadu5571 (2025). https://doi.org/10.1126/sciadv.Adu5571

[64] Chan, H. W. et al. A Pilot Study on MicroRNA Profile in Tear Fluid to Predict Response to Anti-VEGF Treatments for Diabetic Macular Edema. J Clin Med 9 (2020). https://doi.org/10.3390/jcm9092920

[65] Lin, C., Ye, W., Wu, S. & Huang, Z. Blood Cell-Derived Inflammatory Indices in Diabetic Macular Edema: Clinical Significance and Prognostic Relevance. Biomedicines 13 (2025). https://doi.org/10.3390/biomedicines13122979

[66] Malepati, A. & Grant, M. B. The Role and Diagnostic Potential of Insulin-like Growth Factor 1 in Diabetic Retinopathy and Diabetic Macular Edema. Int J Mol Sci 26 (2025). https://doi.org/10.3390/ijms26093961

[67] Lai, D., Wu, Y., Shao, C. & Qiu, Q. The Role of Muller Cells in Diabetic Macular Edema. Invest Ophthalmol Vis Sci 64, 8 (2023). https://doi.org/10.1167/iovs.64.10.8

[68] Rangasamy, S. et al. Chemokine mediated monocyte trafficking into the retina: role of inflammation in alteration of the blood-retinal barrier in diabetic retinopathy. PLoS One 9, e108508 (2014). https://doi.org/10.1371/journal.pone.0108508

[69] Wang, Z. Y. et al. Plasma metabolomic profiling of diabetic macular edema. Sci Rep 15, 10012 (2025). https://doi.org/10.1038/s41598-025-94759-8

[70] Chen, Y. N. et al. Analysis of Total Antioxidant Capacity and Ascorbic Acid Levels in the Aqueous Humor of Patients With Diabetic Retinopathy. Transl Vis Sci Technol 14, 31 (2025). https://doi.org/10.1167/tvst.14.8.31

[71] Vingolo, E. M. et al. Diabetic Macular Edema in Maintenance Intravitreal Scheduling. Pharmaceutics 17 (2025). https://doi.org/10.3390/pharmaceutics17050605

[72] Ferreira, A. M. et al. Intraocular inflammation following intravitreal injections of anti-vascular endothelial growth factor drugs. Graefes Arch Clin Exp Ophthalmol 263, 2885-2892 (2025). https://doi.org/10.1007/s00417-025-06875-w

[73] Cheema, A. A. & Cheema, H. R. Diabetic Macular Edema Management: A Review of Anti-Vascular Endothelial Growth Factor (VEGF) Therapies. Cureus 16, e52676 (2024). https://doi.org/10.7759/cureus.52676

[74] Chan, L. K. Y., Lin, S. S., Chan, F. & Ng, D. S. Optimizing treatment for diabetic macular edema during cataract surgery. Front Endocrinol (Lausanne) 14, 1106706 (2023). https://doi.org/10.3389/fendo.2023.1106706